Merck withdraws Tepmetko’s reimb application
By Lee, Tak-Sun | translator Kim, Jung-Ju
24.04.15 05:50:45
가나다라
0
Was unable to pass the clinical utility hurdle as an anticancer drug that targets MET mutation
Its competitor Tabrecta continues non-reimbursement sales...whether its company will abandon or reattempt reimb at crossroads
#I1 Merck voluntarily withdrew its reimbursement application for its Tepmetko’s Tab (tepotinib) after failing to establish reimbursement standards at the Health Insurance Review and Assessment Service's Cancer Disease Review Committee meeting in March
After two unsuccessful attempts, the industry’s eyes are on whether the company will reapply for reimbursement after reorganizing its application.
According to industry sources on the 14th, Merck recently submitted a document to HIRA to voluntarily withdraw the reimbursement application it had submitted for Tepmetko’s reimbursement.
Tepmetko is a treatment for locally advanced or metastatic non-small cell lung cancer with a c
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)